Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This study involves research. Pregabalin is a Food and Drug Administration (FDA) medication
approved in the United States for the treatment of nerve pain related to diabetes and
post-herpetic neuralgia "shingles", and for seizures in adults. The purpose of this research
is to study the effect of oral Pregabalin on spinal neurotransmitters in subjects undergoing
Total Knee Replacement Surgery (TKA). TKA is associated with considerable postoperative pain
which if unrelieved may result in prolonged hospital stay, inability to participate in
rehabilitation programs, poor outcomes, and greater use of health-care resources. This study
examines the effect of pregabalin administered for TKA on pain-related neurotransmitter
concentrations.